The trajectory of companies tied to Sildenafil's legacy presents a intricate investment picture . While the initial success generated substantial gains, generic alternatives have significantly diminished market share . Investing in related pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving medical chang